Replies to post #241406 on Biotech Values

[DewDiligence]

ABBV’s 2022 sales guidance for Mavyret=$1.7B—flat YoY.

[DewDiligence]

ABBV 1Q22 Mavyert sales=$380M, -11% QoQ:

https://news.abbvie.com/news/press-releases/abbvie-reports-first-quarter-2022-financial-results.htm

The geographic breakdown was: US $169M (-14% QoQ); and ex-US $211M (-8% YoY).

In February, ABBV issued 2022 Mavyret guidance of $1.7B (#msg-167728327); we’ll know after ABBV’s 1Q22 CC whether this guidance still holds.